Oruka Therapeutics
$64.61
48
-$1.07-1.63% Today
Statistics
Day High
65.07
Day Low
62.96
52W High
76.39
52W Low
9.46
Volume
1,217,691
Avg. Volume
-
Mkt Cap
3.13B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Dividends
0%Dividend Yield
Aug 24
$19.36
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A
Earnings
20MayExpected
Expected EPS
-0.546916
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-225.39MNet Income
Analyst Ratings
108.22Average Price Target
The highest estimate is 160.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ORKA. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap179.12B
Pfizer
PFE
Mkt Cap146.36B
Novartis
NVS
Mkt Cap278.64B
Merck
MRK
Mkt Cap275.09B
Bristol-Myers Squibb
BMY
Mkt Cap114.68B
Gilead Sciences
GILD
Mkt Cap163.06B
Abbvie
ABBV
Mkt Cap356.49B
Astrazeneca
AZN
Mkt Cap283.47B
Johnson & Johnson
JNJ
Mkt Cap532.77B
Sanofi
SNY
Mkt Cap103.76B
About
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Show more...
CEO
Dr. Lawrence Otto Klein Ph.D.
Employees
28
Country
United States
ISIN
US6876041087
Listings
0 Comments
Share your thoughts
FAQ
What is Oruka Therapeutics stock price today?▼
The current price of ORKA is $64.61 USD — it has decreased by -1.63% in the past 24 hours. Watch Oruka Therapeutics stock price performance more closely on the chart.
What is Oruka Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oruka Therapeutics stocks are traded under the ticker ORKA.
Is Oruka Therapeutics stock price growing?▼
ORKA stock has fallen by -6.29% compared to the previous week, the month change is a +8.44% rise, over the last year Oruka Therapeutics has showed a +562.67% increase.
What is Oruka Therapeutics market cap?▼
Today Oruka Therapeutics has the market capitalization of 3.13B
When is the next Oruka Therapeutics earnings date?▼
Oruka Therapeutics is going to release the next earnings report on May 20, 2026.
What were Oruka Therapeutics earnings last quarter?▼
ORKA earnings for the last quarter are -0.45 USD per share, whereas the estimation was -0.64 USD resulting in a +29.26% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Oruka Therapeutics revenue for the last year?▼
Oruka Therapeutics revenue for the last year amounts to 0 USD.
What is Oruka Therapeutics net income for the last year?▼
ORKA net income for the last year is -225.39M USD.
Does Oruka Therapeutics pay dividends?▼
Yes, ORKA dividends are paid en. The last dividend per share was 19.36 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Oruka Therapeutics have?▼
As of May 12, 2026, the company has 28 employees.
In which sector is Oruka Therapeutics located?▼
Oruka Therapeutics operates in the Health & Wellness sector.
When did Oruka Therapeutics complete a stock split?▼
The last stock split for Oruka Therapeutics was on September 03, 2024 with a ratio of 1:12.
Where is Oruka Therapeutics headquartered?▼
Oruka Therapeutics is headquartered in Menlo Park, United States.